Search results
Pfizer’s first gene therapy gets approval for clotting disorder
San Francisco Chronicle· 4 days agoPfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business. The treatment, called Beqvez ...
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
Motley Fool via Yahoo Finance· 2 days agoHowever, Pfizer also faces the looming loss of exclusivity for multiple products. Despite this bad...
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Zacks via Yahoo Finance· 6 days agoPfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings...
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks via Yahoo Finance· 4 days agoBeyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of...
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Benzinga via Yahoo Finance· 4 days agoFriday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate...
The Motley Fool: Pfizer offers a pfat 6.4% dividend
Dallas Morning News· 2 days agoShares of Pfizer were recently down more than 35% over the past year — in part because the market’s enthusiasm for its COVID-19 vaccine Comirnaty and...
Pfizer's Options: A Look at What the Big Money is Thinking - Pfizer (NYSE:PFE)
Benzinga· 4 days agoThese metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and ...
Pfizer (PFE) Scheduled to Post Quarterly Earnings on Wednesday
ETF DAILY NEWS· 7 days agoPfizer (NYSE:PFE – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 1st. Pfizer has set its ...
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy
Investor's Business Daily· 4 days agoPfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.
FDA Approves Second Gene Therapy for Hemophilia B
Medscape· 4 days agoPfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.